Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborators:

National Heart, Lung, and Blood Institute (NHLBI)

Merck

Information provided by (Responsible Party):

Priscilla Hsue, University of California, San Francisco

ClinicalTrials.gov Identifier:

NCT00843713

First received: February 12, 2009

Last updated: May 16, 2013

Last verified: May 2013

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	February 2014
Estimated Primary Completion Date:	November 2013 (Final data collection date for primary outcome measure)

No publications provided by University of California, San Francisco

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hatano H, Scherzer R, Wu Y, Harvill K, Maka K, Hoh R, Sinclair E, Palmer S, Martin JN, Busch MP, Deeks SG, Hsue PY. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):317-25. doi: 10.1097/QAI.0b013e31826e7d0f.

To Top